Kun Meng
Chief Executive Officer at Shenogen Pharma Group Ltd.
Profile
Kun Meng is the founder of Shenogen Pharma Group Ltd.
and Beijing Shenogen Pharma Group Ltd., where he holds the titles of Chairman & Chief Executive Officer and Chairman & General Manager, respectively.
Both companies were founded in 2006.
Dr. Meng received a doctorate degree from the University of Chinese Academy of Sciences in 1992 and a graduate degree from Harvard University in 2000.
Kun Meng active positions
| Companies | Position | Start |
|---|---|---|
Shenogen Pharma Group Ltd.
 Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Shenogen Pharma Group Ltd. manufactures pharmaceutical products. It develops therapeutics for cancer treatment. The firm’s product pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. The company was founded by Kun Meng, Jing Li, Karen Liu and Zhaoyi Wang in 2006 and is headquartered in Beijing, China. | Chief Executive Officer | 2005-12-31 |
Beijing Shenogen Pharma Group Ltd.
 Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Chief Executive Officer | 2005-12-31 |
Training of Kun Meng
| University of Chinese Academy of Sciences | Doctorate Degree |
| Harvard University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Shenogen Pharma Group Ltd.
Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Shenogen Pharma Group Ltd. manufactures pharmaceutical products. It develops therapeutics for cancer treatment. The firm’s product pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. The company was founded by Kun Meng, Jing Li, Karen Liu and Zhaoyi Wang in 2006 and is headquartered in Beijing, China. | Health Technology |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Health Technology |
- Stock Market
- Insiders
- Kun Meng